Stock Market Reviews

VKTX (Viking Therapeutics, Inc.) News

Get the latest news, insights, and market updates on VKTX (Viking Therapeutics, Inc.). Explore the news page 1 on MyTopStock.com for investor discussions, analysis, and real-time stock performance coverage.

• Here's How VKTX's Obesity Drug Is Moving Quickly Through Phase III
  Viking Therapeutics' obesity drug VK2735 is racing through phase III, with one pivotal study fully enrolled just months after launch.
  Jan 2, 2026 - $VKTX
• 2 Beaten-Down Stocks That Could Bounce Back in 2026
  It's not time to give up on these companies yet.
  Dec 31, 2025 - $VKTX
• Viking Therapeutics, Inc. (VKTX) Sees a More Significant Dip Than Broader Market: Some Facts to Know
  In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $35.32, marking a -3.13% move from the previous day.
  Dec 30, 2025 - $VKTX
• This Small But Mighty Stock Could Surprise Investors in 2026
  This under-the-radar biotech stock is setting up for a big 2026.
  Dec 29, 2025 - $VKTX
• Viking Therapeutics (VKTX) Is Up 8.9% After Rival Data Bolsters Its Oral Obesity Program
  In recent days, analyst Joseph Pantginis of H.C. Wainwright reaffirmed a positive stance on Viking Therapeutics after competitor Eli Lilly’s successful Phase 3 oral obesity study appeared to support Viking’s own oral obesity drug program. This external validation of Viking’s lead candidate VK2735 has sharpened investor focus on the company’s potential role in the rapidly evolving obesity treatment market. We’ll now examine how this strengthened confidence in VK2735’s commercial prospects...
  Dec 25, 2025 - $VKTX
• Wall Street Bulls Look Optimistic About Viking Therapeutics (VKTX): Should You Buy?
  The average brokerage recommendation (ABR) for Viking Therapeutics (VKTX) is equivalent to a Buy. The overly optimistic recommendations of Wall Street analysts make the effectiveness of this highly sought-after metric questionable. So, is it worth buying the stock?
  Dec 23, 2025 - $VKTX
• Viking Therapeutics, Inc. (VKTX) Beats Stock Market Upswing: What Investors Need to Know
  In the latest trading session, Viking Therapeutics, Inc. (VKTX) closed at $36.41, marking a +2.85% move from the previous day.
  Dec 23, 2025 - $VKTX
• Novo Nordisk Jumps As FDA OKs Wegovy Pill As First-Ever Oral GLP-1 Weight Loss Drug
  The FDA approved Novo Nordisk's Wegovy pill as the first oral GLP-1 treatment for weight loss. The Danish drug giant jumped.
  Dec 23, 2025 - $VKTX
• Premarket Movers: Albemarle Gaining Momentum on Lithium Boom
  Albemarle (NYSE: ALB) had an incredible year. Since bottoming out at around $50 in April, the lithium giant exploded to $145.38. This morning, it’s up another $4.15 and could race even higher, especially with Ganfeng Lithium Chairman LI Liangbin noting that demand could rise 30% to 50% next year. In addition, according to Sprott, the ... Premarket Movers: Albemarle Gaining Momentum on Lithium Boom
  Dec 23, 2025 - $VKTX
• Here is Why H.C. Wainwright Sees Immense Upside for Viking Therapeutics (VKTX)
  Viking Therapeutics (NASDAQ:VKTX) is one of the most promising mid-cap healthcare stocks under $50. On December 18, H.C. Wainwright analyst Joseph Pantginis reaffirmed his Buy rating on Viking Therapeutics (NASDAQ:VKTX). The analyst has forecasted a huge upside potential of almost 190% from the prevailing range, with a price target of $102 a share. Pantginis maintains […]
  Dec 22, 2025 - $VKTX